Beigene Ltd 6160-HK:Hong Kong Stock Exchange

*Data is delayed | Exchange | HKD
Last | 2:00 PM CTT
97.50quote price arrow down-1.45 (-1.47%)
Volume
410,800
52 week range
75.45 - 154.80
Loading...
  • Open98.50
  • Day High98.85
  • Day Low97.00
  • Prev Close98.95
  • 52 Week High154.80
  • 52 Week High Date05/08/23
  • 52 Week Low75.45
  • 52 Week Low Date04/19/24

Key Stats

  • Market Cap17,011.56M
  • Shares Out1,359.51M
  • 10 Day Average Volume1.54M
  • Dividend-
  • Dividend Yield-
  • Beta0.61
  • YTD % Change-11.44

KEY STATS

  • Open98.50
  • Day High98.85
  • Day Low97.00
  • Prev Close98.95
  • 52 Week High154.80
  • 52 Week High Date05/08/23
  • 52 Week Low75.45
  • 52 Week Low Date04/19/24
  • Market Cap17,011.56M
  • Shares Out1,359.51M
  • 10 Day Average Volume1.54M
  • Dividend-
  • Dividend Yield-
  • Beta0.61
  • YTD % Change-11.44

RATIOS/PROFITABILITY

  • EPS (TTM)-5.08
  • P/E (TTM)-19.19
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Beigene Ltd

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small...
John Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Xiaobin Wu
President, Chief Operating Officer, General Manager - China
Julia Wang
Chief Financial Officer
Address
94 Solaris Avenue,, Camana Bay
Grand Cayman, BEJ
KY1-1108
Cayman Islands